Buscar
Mostrando ítems 11-20 de 23
Biomarker Candidates for Alzheimer’s Disease Unraveled through In Silico Differential Gene Expression Analysis
(Basel, 2022-05-07)
Alzheimer’s disease (AD) is neurodegeneration that accounts for 60–70% of dementia cases.
Symptoms begin with mild memory difficulties and evolve towards cognitive impairment. The
underlying risk factors remain primarily ...
A Novel Automatic Quantification Protocol for Biomarkers of Tauopathies in the Hippocampus and Entorhinal Cortex of Post-Mortem Samples Using an Extended Semi-Siamese U-Net
(Biology., 2022-07-28)
Efforts have been made to diagnose and predict the course of different neurodegenerative
diseases through various imaging techniques. Particularly tauopathies, where the tau polypeptide
is a key participant in molecular ...
Current status and challenges of stem cell treatment for Alzheimer’s disease
(Journal of Alzheimer’s Disease, 2021)
Neurodegenerative diseases called tauopathies, such as Alzheimer’s disease (AD), frontotemporal dementia, progressive supranuclear palsy, and Parkinson’s disease, among others, are characterized by the pathological processing ...
The impact of SARS-CoV-2 in dementia across Latin America: A call for an urgent regional plan and coordinated response
(Translational Research & Clinical Interventions, 2020)
The SARS-CoV-2 global pandemic will disproportionately impact countries with weak economies and vulnerable populations including people with dementia. Latin American and Caribbean countries (LACs) are burdened with unstable ...
Prediction of dementia risk in low-income and middleincome countries (the 10/66 Study): an independent external validation of existing models
(Elsevier Ltd., 2020-04)
To date, dementia prediction models have been exclusively developed and tested in high-income countries (HICs). However, most people with dementia live in low-income and middle-income countries (LMICs), where dementia risk ...
Dementia attributable healthcare utilizations in the Caribbean versus United States
(Journal of Alzheimer's Disease, 2023-11-07)
Despite the high burden of Alzheimer's disease and other dementias among the Hispanic population worldwide, little is known about how dementia affects healthcare utilizations among this population outside of the US, in ...
FMNL2 regulates gliovascular interactions and is associated with vascular risk factors and cerebrovascular pathology in Alzheimer’s disease
(Acta Neuropathologica (2022) 144:59–79, 2022-05-24)
Alzheimer’s disease (AD) has been associated with cardiovascular and cerebrovascular risk factors (CVRFs) during middle
age and later and is frequently accompanied by cerebrovascular pathology at death. An interaction ...
Progranulin mutations in clinical and neuropathological Alzheimer’s disease
(Alzheimers Dement., 2022-12-10)
Progranulin (GRN) mutations occur in frontotemporal lobar degeneration
(FTLD) and in Alzheimer’s disease (AD), often with TDP-43 pathology.
We determined the frequency of rs5848 and rare, pathogenic GRN mutations
in two ...
Neurovascular dysfunction and vascular amyloid accumulation as early events in Alzheimer's disease
(Metabolic Brain Disease, 2021-07)
Alzheimer's disease (AD) is clinically characterized by a progressive loss of cognitive functions and short-term memory. AD patients present two distinctive neuropathological lesions: neuritic plaques and neurofibrillary ...
Prevalence and impact of neuropsychiatric symptoms in normal aging and neurodegenerative syndromes: A population-based study fromLatin America
(Alzheimer’s Dement, 2023-06-23)
Neuropsychiatric symptoms (NPSs) are common in neurodegenerative diseases; however, little is known about the prevalence of NPSs in Hispanic populations. Neuropsychiatric symptoms (NPSs) are common in neurodegenerative ...